| abstract |
The present invention provides novel therapeutic molecules called Culling Fusion Proteins (CFPs) that allow the continuous removal of therapeutic targets from extracellular space by exploiting the endosome/lysosome intracellular degradation pathway, and the exocytotic pathway in a combined manner. The products of the invention, by appropriately utilizing the cellular endocytosis and exocytosis mechanism, can be recycled multiple times by cells to eliminate undesired molecules, therefore such therapeutic molecules can be administered at low concentration. |